Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02207504
Title Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

prostate adenocarcinoma


Crizotinib + Enzalutamide

Age Groups: adult
Covered Countries USA

No variant requirements are available.